Septerna

Septerna Pre-Tax Margin

The Pre-Tax Profit Margin of Septerna (SEPN) as of Oct 29, 2026 is -106.35 %. In the previous year, Pre-Tax Profit Margin was -6,725.21 % — a change of -98.42% (higher).

Pre-Tax Margin

-106.35 %

YoY

-98.42%

Last updated:

Pre-Tax Profit Margin of Septerna is 2025 -106.35 % . Pre-Tax Profit Margin of Septerna was 2024 -6,725.21 % . It decreases by -98.42% higher compared to the previous year.

The Septerna Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2023
3,225.83 USD
Jan 1, 2024
-6,725.21 USD
Jan 1, 2025
-106.35 USD
The Septerna Pre-Tax Margin history
YEARPre-Tax MarginYoY
-106.35 %-98.42%
-6,725.21 %-308.48%
3,225.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Septerna Stock analysis

What does Septerna do? Septerna, Inc. develops oral small molecule GPCR-targeted drugs using its proprietary Native Complex PlatformTM. The company focuses on endocrinology, immunology, and inflammation, and metabolic diseases. Its pipeline targets GPCRs for the first time, uncovering novel binding pockets and pursuing various pharmacologies like agonists and antagonists. The firm advances a deep portfolio of programs for patients with significant unmet needs. Septerna's products are developed for pharmaceutical companies seeking novel drug discovery platforms. The company's Native Complex PlatformTM enables industrial-scale GPCR targeting, offering solutions for diseases with high unmet medical needs. Its therapeutic areas include endocrinology, immunology, and inflammation, and metabolic diseases, targeting patients requiring innovative treatments. The company's pipeline includes oral small molecule drug candidates for GPCR-targeted therapies. These candidates are designed to address conditions in endocrinology, immunology, and inflammation, and metabolic diseases. Septerna's approach focuses on uncovering novel binding pockets and pursuing diverse pharmacologies to achieve therapeutic effects. The firm's programs target patients with significant unmet needs across multiple therapeutic areas. Septerna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Septerna stock

Pre-Tax Profit Margin of Septerna is -106.35 % in 2025.

Pre-Tax Profit Margin of Septerna changed from -6,725.21 % to -106.35 %, representing a -98.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Septerna since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Septerna with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Septerna

All Key Metrics — Septerna